DarioHealth Corp (DRIO)
NASDAQ:DRIO
Want to see DRIO full AI Analyst Report?
DRIO Stock Chart & Stats
$11.72
-$0.63(-41.18%)
At close: 4:00 PM EST
$11.72
-$0.63(-41.18%)
Day’s Range― - ―
52-Week Range$5.94 - $17.74
Previous CloseN/A
Volume780.96K
Average Volume (3M)33.32K
Market Cap
$55.94M
Enterprise Value$68.22M
Total Cash (Recent Filing)$20.26M
Total Debt (Recent Filing)$31.82M
Price to Earnings (P/E)6.0
Beta0.49
Next Earnings
Aug 17, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.25
Shares Outstanding7,312,398
10 Day Avg. Volume41,359
30 Day Avg. Volume33,324
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)8.32
Price to Sales (P/S)25.26
P/FCF Ratio-21.65
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue3.22
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda-1.95
Forecast
1Y Price Target
$10.50Price Target Upside-10.41% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.79
Revenue Forecast (FY)$26.16M
Bulls Say, Bears Say
Bulls Say
High B2B2C Gross MarginsSustained ~80% non‑GAAP B2B2C gross margins (nine consecutive quarters) and a Q1 consolidated gross margin of 57% indicate durable unit economics. High unit margins reduce incremental capital needs per new covered life, enabling scalable margin expansion as partner channels and recurring contracts grow.
Large Commercial Pipeline & Account WinsA reported ~$127M commercial pipeline and steady account additions signal meaningful sales momentum and a backlog of contract opportunities. Successful conversion over 2–3 quarters would translate into recurring B2B revenue, supporting multi‑period top‑line durability via enterprise and channel agreements.
Proprietary Data & Clinical EvidenceOwnership of >13B real‑world data points plus 100+ peer‑reviewed studies builds a durable data moat and clinical credibility. These assets enhance AI personalization, support outcomes- and claims‑based contracting with payers/providers, and differentiate the platform in long‑term procurement decisions.
Bears Say
Persistent Negative Cash FlowConsistently negative operating and free cash flow indicate ongoing cash burn and reliance on external financing or balance-sheet resources. This constrains the pace of commercial investment, increases dilution risk from future raises, and makes the business sensitive to delays in partner revenue conversion.
Earnings Quality & Operating LossesReported TTM net income contrasts with persistent GAAP and non‑GAAP operating losses and negative EBITDA margins, signaling earnings‑quality concerns. Sustainable profitability remains dependent on achieving scale, converting contracted pipeline, and maintaining disciplined OpEx as revenue growth steadies.
Dependence On Channel ConversionsGrowth is increasingly driven by large partner-led deployments that require integrations and eligibility work. This concentration creates timing and execution risk: delayed conversions directly defer revenue recognition, compress margins short‑term, and can strain cash runway if multiple deals slip.
DarioHealth News
DRIO FAQ
What was DarioHealth Corp’s price range in the past 12 months?
DarioHealth Corp lowest stock price was $5.93 and its highest was $17.74 in the past 12 months.
What is DarioHealth Corp’s market cap?
DarioHealth Corp’s market cap is $55.94M.
When is DarioHealth Corp’s upcoming earnings report date?
DarioHealth Corp’s upcoming earnings report date is Aug 17, 2026 which is in 73 days.
How were DarioHealth Corp’s earnings last quarter?
DarioHealth Corp released its earnings results on May 13, 2026. The company reported -$1.25 earnings per share for the quarter, beating the consensus estimate of -$1.48 by $0.23.
Is DarioHealth Corp overvalued?
According to Wall Street analysts DarioHealth Corp’s price is currently Overvalued.
Does DarioHealth Corp pay dividends?
DarioHealth Corp does not currently pay dividends.
What is DarioHealth Corp’s EPS estimate?
DarioHealth Corp’s EPS estimate is -1.22.
How many shares outstanding does DarioHealth Corp have?
DarioHealth Corp has 7,312,398 shares outstanding.
What happened to DarioHealth Corp’s price movement after its last earnings report?
DarioHealth Corp reported an EPS of -$1.25 in its last earnings report, beating expectations of -$1.48. Following the earnings report the stock price went down -6.682%.
Which hedge fund is a major shareholder of DarioHealth Corp?
Currently, no hedge funds are holding shares in DRIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DarioHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.65%
12-Months-Change
Fundamentals
Return on Equity
93.18%
Trailing 12-Months
Asset Growth
-10.66%
Trailing 12-Months
Company Description
DarioHealth Corp
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
DRIO Company Deck
DRIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized sequential revenue growth, a materially improved cost structure, a sizeable commercial pipeline ($127M) and expanding channel distribution (targeting >175M covered lives), supported by proprietary data assets and early AI-driven engagement gains. Key positives include meaningful OpEx reductions, improving margins on core B2B2C offerings (~80% non-GAAP gross margin), a clear strategic push to participate in care- and outcomes-based revenue via partnerships, and accelerating consumer product demand. Offsetting these positives are a year-over-year revenue decline tied to deliberate removal of non-recurring pharmaceutical revenue, continued GAAP and non-GAAP operating losses, dependence on the timing of large partner conversions (implementation and onboarding risks), limited near-term revenue visibility and an ongoing strategic review that introduces some uncertainty. On balance, management presented measurable operational improvements and a clear path toward scaled, higher-margin channel revenue, while acknowledging conversion and timing risks that remain to be resolved.View all DRIO earnings summariesDRIO Stock 12 Month Forecast
Average Price Target
$10.50
▼(-10.41% Downside)
Technical Analysis
Ownership Overview
7.32% Insiders
1.59% Mutual Funds
8.36% Other Institutional Investors
81.82% Public Companies and
Individual Investors